Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KC-5260

NCI-H929-BCMA-KO Cell Line

Home » NCI-H929-BCMA-KO Cell Line

Background of NCI-H929-BCMA-KO Cell Line

BCMA, i.e., CD269 or TNFRSF17, is a TNF receptor superfamily 17 member, expressed on differentiated plasma cells and plasmablasts under physiological conditions and nearly on all MM tumor cells. BCMA ligands include APRIL (A Proliferations-Inducing Ligand) and BAFF (B-cell activating factor) which are involved in the maturation and differentiation of PCs. APRIL can bind to BCMA more avidly than to BAFF, and both can induce BCMA downstream signals to PI3K-PKB/Akt (i.e., phosphoinositide-3-kinase-protein kinase B/Akt), to RAS/MAPK (i.e., rat sarcoma/mitogen-activated protein kinase), and also to NF-κB (i.e., nuclear factor kappa-B), inducing increased plasma cells proliferation and survival.

Specifications

Catalog Number:
KC-5260
Cell Line Name:
NCI-H929-BCMA-KO Cell Line
Clone Number
3B2
Host Cell Line:
NCI-H929
Description:
Stable NCI-H929 clone with human BCMA gene knockout, No.3B2
Quantity:
Two vials of frozen cells (over than 5×106)
Stability:
Stable in culture over a minimum of 10 passages
Application:
Drug screening and biological assays
Freezing Medium:
RPMI1640+20% FBS+10% DMSO
Propagation Medium:
RPMI1640+10% FBS+0.05mM 2-mercaptoethanol
Selection Marker:
NA
Morphology:
lymphoblast
Subculture:
Split saturated culture 1:5-1:7 every 2-3 days; seed out at about 1-3 × 105 cells/mL
Incubation:
37 °C with 5% CO2
Storage:
Liquid nitrogen immediately upon receiving
Doubling Time:
Approximately 50 hours
Mycoplasma Status:
Negative
In Vivo Validation:

Cell Line Generation

NCI-H929-BCMA-KO cell line was generated using the CRISPR method.

Characterization

Figure 1: Characterization of NCI-H929-BCMA-KO cell line stable clone using PCR sequencing.

Figure 2: Characterization of NCI-H929-BCMA-KO cell line stable clone using RT-PCR sequencing.

Figure 3: Characterization of NCI-H929-BCMA-KO cell line stable clone using FACS.

Cell Resuscitation

  1. Prewarm culture medium (RPMI1640 + 10% FBS) in a 37°C water bath.
  2. Thaw the frozen vial in a 37°C water bath for 1-2 minutes.
  3. Transfer the vial into biosafety cabinet, and wipe the surface with 70% ethanol.
  4. Unscrew the top of the vial and transfer the cell suspension gently into a sterile centrifuge tube containing 9.0mL complete culture medium.
  5. Spin at ~ 125 × g for 5-7 minutes at room temperature, and discard the supernatant without disturbing the pellet.
  6. Resuspend cell pellet with the appropriate volume of complete medium and transfer the cell suspension into a T25 culture flask.
  7. Incubate the flask at 37°C, 5% CO2 incubator.
  8. Split saturated culture 1:5-1:7 every 2-3 days; seed out at about 1-3 ×105 cells/mL.

Cell Freezing

  1. Prepare the freezing medium (70% RPMI1640 + 20% FBS + 10% DMSO) fresh immediately before use.
  2. Keep the freezing medium on ice and label cryovials.
  3. Transfer cells to a sterile, conical centrifuge tube, and count the cells.
  4. Centrifuge the cells at 250×g for 5 minutes at room temperature and carefully aspirate off the medium.
  5. Resuspend the cells at a density of at least 3×106 cells/mL in chilled freezing medium.
  6. Aliquot 1 mL of the cell suspension into each cryovial.
  7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer.
  8. Transfer vials to liquid nitrogen for long-term storage.

References

  1. Tan CR, Shah UA. Targeting BCMA in Multiple Myeloma. Curr Hematol Malig Rep. 2021 Oct;16(5):367-383. doi: 10.1007/s11899-021-00639-z. Epub 2021 Aug 25. PMID: 34432234; PMCID: PMC9655650.
  2. Sammartano V, Franceschini M, Fredducci S, Caroni F, Ciofini S, Pacelli P, Bocchia M, Gozzetti A. Anti-BCMA novel therapies for multiple myeloma. Cancer Drug Resist. 2023 Mar 22;6(1):169-181. doi: 10.20517/cdr.2022.138. PMID: 37065871; PMCID: PMC10099603.